Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
STATE OF NEW YORK
________________________________________________________________________
9010
2025-2026 Regular Sessions
IN ASSEMBLY
August 13, 2025
___________
Introduced by M. of A. ROSENTHAL -- read once and referred to the
Committee on Health
AN ACT to amend the public health law, in relation to requiring practi-
tioners to discuss certain risks with a patient who is being
prescribed a controlled substance or an opioid analgesic
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Subdivision 9 of section 3331 of the public health law, as
2 added by chapter 732 of the laws of 2022, is amended to read as follows:
3 9. (a) When a patient seeks treatment for any neuromusculoskeletal
4 condition that causes pain, where a practitioner considers [an opioid
5 treatment] prescription of a schedule II controlled substance for the
6 treatment of pain or any other opioid drug which is a prescription drug
7 for acute or chronic pain and again prior to issuing the third
8 prescription of the course of treatment, the practitioner shall consid-
9 er, discuss with the patient as set forth in paragraph (b) of this
10 subdivision, and, as appropriate, refer or prescribe non-opioid treat-
11 ment alternatives, based on the practitioner's clinical judgment and
12 following generally accepted national professional or treatment guide-
13 lines, and consistent with patient preference and consent, before start-
14 ing a patient on opioid treatment. For the purposes of this subdivision,
15 non-opioid treatment alternatives include, but are not limited to:
16 acupuncture, chiropractic, massage therapy, physical therapy, occupa-
17 tional therapy, cognitive behavioral therapy, non-opioid medications,
18 interventional treatments and non-clinical activities such as exercise.
19 The practitioner shall inform the patient that some treatments may not
20 be covered by the patient's health coverage.
21 (b) A practitioner shall discuss with the patient, or the patient's
22 parent or guardian if the patient is under eighteen years of age and is
23 not an emancipated minor, the risks associated with the drugs being
24 prescribed, including but not limited to:
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD11164-01-5
A. 9010 2
1 (i) the risks of addiction and overdose associated with opioid drugs
2 and the dangers of taking opioid drugs with alcohol, benzodiazepines and
3 other central nervous system depressants;
4 (ii) the reasons why the prescription is necessary;
5 (iii) alternative treatments that may be available; and
6 (iv) the risks associated with the use of the drugs being prescribed,
7 specifically that opioids are highly addictive, even when taken as
8 prescribed, that there is a risk of developing a physical or psycholog-
9 ical dependence on the controlled substance, and that the risks of
10 taking more opioids than prescribed, or mixing sedatives, benzodiaze-
11 pines or alcohol with opioids, can result in fatal respiratory
12 depression.
13 (c) The department shall develop and make available to practitioners
14 guidelines for the discussion required by this subdivision.
15 (d) The requirements of this subdivision shall not apply for patients
16 being treated under any of the following circumstances: treatment of
17 cancer; hospice or other end-of-life care; post-surgery treatment imme-
18 diately following a surgical procedure; or in a medical emergency. For
19 purposes of this subdivision, "medical emergency" means an acute injury
20 or illness that poses an immediate risk to a person's life or health.
21 § 2. Paragraph (a) of subdivision 3 of section 3309 of the public
22 health law is amended by adding a new subparagraph (vii) to read as
23 follows:
24 (vii) "Opioid analgesics" means the medicines buprenorphine, butorpha-
25 nol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine,
26 methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine,
27 propoxyphene as well as their brand names, isomers and combinations.
28 § 3. Subdivision 7 of section 3309 of the public health law, as added
29 by chapter 803 of the laws of 2021, is amended to read as follows:
30 7. [With] For the first opioid analgesic prescription [to a particular
31 patient] of [an opioid of each] a calendar year that is greater than a
32 one week's supply, for use in a setting other than a general hospital or
33 nursing home under article twenty-eight of this chapter or facility
34 under article thirty-one of the mental hygiene law, or when a practi-
35 tioner is prescribing a controlled substance to a patient under the care
36 of hospice as defined by section four thousand two of this chapter, the
37 prescriber shall counsel the patient on the risks of overdose, and
38 prescribe an opioid antagonist when any of the following risk factors
39 are present: (a) a history of substance use disorder; (b) high dose or
40 cumulative prescriptions that result in ninety morphine milligram equiv-
41 alents or higher per day; (c) concurrent use of opioids and benzodiaze-
42 pine or nonbenzodiazepine sedative hypnotics.
43 § 4. This act shall take effect immediately.
